Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Immunizations and infections

AC Alejo Chorny
SC Sandra Casas-Recasens
JS Jordi Sintes
MS Meimei Shan
NP Nadia Polentarutti
RG Ramón García-Escudero
AW A. Cooper Walland
JY John R. Yeiser
LC Linda Cassis
JC Jorge Carrillo
IP Irene Puga
CC Cristina Cunha
HB Hélder Bastos
FR Fernando Rodrigues
JL João F. Lacerda
AM António Morais
RD Rebeca Dieguez-Gonzalez
PH Peter S. Heeger
GS Giovanni Salvatori
AC Agostinho Carvalho
AG Adolfo Garcia-Sastre
JB J. Magarian Blander
AM Alberto Mantovani
CG Cecilia Garlanda
AC Andrea Cerutti
request Request a Protocol
ask Ask a question
Favorite

Mice were i.v. or i.p. immunized with 5 µg TNP-Ficoll, 5 µg TNP-LPS (LGC Biosearch Technologies), 2.87 µg Pneumovax 23 (Merck), or 50 µg NP-OVA supplemented with alum (LGC Biosearch Technologies). Mice were also i.v. infected with 2 × 107 SP (CPS-14) or i.n. infected with 100 PFU mouse-adapted human influenza virus A/PR/8/34 (PR8). In some experiments, SP was treated with mitomycin to inhibit bacterial proliferation. Lung tissue was processed to determine viral titers by plaque-forming assays.

Copyright and License information:  ©2016 Chorny et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A